ZYBT Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -11.31%, SMA50 -29.76%, SMA200 -81.77%). The stock’s 14-day RSI is 36.24 (weak momentum), while the ATR of 0.12 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -94.34% below its high and over 12.43% above its low. Average 10-day trading volume of 99.39 thousand shares is significantly above the 3-month average of 24.88 thousand, indicating heightened recent market interest.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) closed at $0.71 USD, losing -$0.38 (-34.86%) from the previous close of $1.09. The stock is currently within 5% of its 52-week low $0.68 and $14.30. With a market capitalization of about $33.65 million, Zhengye Biotechnology Holding Limited is classified as a micro-cap and shows lower-than-market volatility (beta ~-4.21). Key stats such as the average daily volume over the past year has been around 26.08 thousand shares, trading with heavier-than-usual volume. Headquartered in Jilin, None, Zhengye Biotechnology Holding Limited operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Songlin Song, the company employs approximately 278 people and listed since January 07, 2025. Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China.

Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) shares are flat -4.35% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Zhengye Biotechnology Holding Limited trading at a premium to the broader market with a P/E of 0.0. Our AI forecast model points to short-term strength (15.49% over two weeks), a medium-term fall (-35.21% over three months), and a longer-term loss (-97.18% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Zhengye Biotechnology Holding Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 15.49%, with price expected at $0.82 by April 03, 2026, within a range of $0.72 to $0.92 3-Month Outlook: Projected fall of -35.21%, reaching $0.46 by June 18, 2026, with a range of $0.06 to $0.81. 1-Year Outlook: Projected loss of -97.18%, with price at $0.02 by March 19, 2027, within a range of $0.00 to $0.31.

Zhengye Biotechnology Holding Limited trades at a P/E ratio of 0.0, slightly below the S&P 500 average, with a price-to-sales ratio of 1.24 The P/FCF stands at 17.45, also above market averages.